免疫检查点抑制剂在肝细胞癌中的进展及展望

摘要/Abstract

摘要：

细胞毒性T淋巴细胞相关抗原4（cytotoxic T lymphocyte-associated antigen 4, CTLA-4）,程序性细胞死亡蛋白1（programmed cell death protein-1, PD-1）和程序性细胞死亡配体1（programmed cell death ligand 1, PD-L1）等免疫检查点能抑制抗肿瘤免疫应答,免疫检查点抑制剂的使用（Immune checkpoint inhibitors,ICIs）拓宽了肿瘤临床治疗理念。临床研究表明,ICIs使更多的肝细胞癌（hepatocellular carcinoma,HCC）患者生存获益,主要表现在部分患者中产生了显著且持久的应答,但同时也存在原发性或适应性耐药。HCC的ICIs联合治疗策略正在1、2或3期试验中进行评估,部分结果表明ICIs与分子靶向药物及局部治疗等联合使用为HCC治疗提供了更为有效的策略。在本综述中,我们总结了ICIs及其联合治疗的最新进展,探讨ICIs在HCC治疗中有效的预测标志物及联合模式选择。

关键词: 肝细胞癌, 免疫检查点抑制剂, 纳武单抗, 帕博利珠单抗, 阿特珠单抗, 免疫治疗, 靶向治疗

Abstract:

Inhibitory checkpoints, including cytotoxic T lymphocyte?Cassociated antigen 4 (CTLA-4), programmed cell death protein-1(PD-1), and programmed cell death ligand 1 (PD-L1), have been identified to suppress anti-tumor immune responses in solid tumors. The application of immune checkpoint inhibitors (ICIs) have reversed immune exhaustion with promising efficacy in practice, which expanded the spectrum of clinical use. Recent output studies show immune checkpoint therapy provides survival benefit for tremendous numbers of patients with hepatocellular carcinoma(HCC). While with remarkable and durable responses in a subset HCC patients, majority of those will still develop primary non-response or adaptive resistance. The combination treatment strategies with immunotherapy is being evaluated in phase 1, 2 or 3 trials in HCC, and some of the results suggested that an anti-PD-1 antibody combined with other ICIs, Tyrosine Kinase Inhibits（TKI）, systemic therapy or locoregional therapy are more effective treatment strategies. In this review, we summarise recent developments in ICIs-based therapies, and speculate rational deployment of the effective predictive markers and selection of the combination therapy strategies,which should hold promise for improve the efficacy and prognosis of HCC patients.

Key words: hepatocellular carcinoma, immune checkpoint inhibitors, HCC, pembrolizumab, nivolumab, Atezolizumab, targeted therapies

何萌, 吕宁, 赵明. 免疫检查点抑制剂在肝细胞癌中的进展及展望[J]. 肝癌电子杂志, 2019, 6(4): 14-19.

Meng HE, Ning Lyu, Ming ZHAO. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Research Progress and Future Perspectives[J]. Electronic Journal of Liver Tumor, 2019, 6(4): 14-19.

参考文献 60

[1]	Villanueva A . Hepatocellular Carcinoma[J]. N Engl J Med, 2019,380(15):1450-1462.
[2]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424.
[3]	Llovet J M, Ricci S, Mazzaferro V , et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008,359(4):378-390.
[4]	Ikeda K, Kudo M, Kawazoe S , et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J]. JOURNAL OF GASTROENTEROLOGY, 2017,52(4):512-519.
[5]	Bruix J, Qin S, Merle P , et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. LANCET, 2017,389(10064):56-66.
[6]	Abou-Alfa G K, Meyer T, Cheng A L , et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018,379(1):54-63.
[7]	Zhu A X, Kang Y, Yen C , et al. REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.[J]. Journal of Clinical Oncology, 2018,36(15_suppl):4003.
[8]	Fang W B, Yao M, Cheng N . Priming cancer cells for drug resistance: role of the fibroblast niche[J]. Front Biol (Beijing), 2014,9(2):114-126.
[9]	Biomed R I . Retracted: The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies[J]. Biomed Res Int, 2016,2016:2514067.
[10]	Dong P, Ma L, Liu L , et al. CD86(+)/CD206(+), Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis[J]. Int J Mol Sci, 2016,17(3):320.
[11]	Arihara F, Mizukoshi E, Kitahara M , et al. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis[J]. Cancer Immunol Immunother, 2013,62(8):1421-1430.
[12]	Miamen A G, Dong H, Roberts L R . Immunotherapeutic approaches to hepatocellular carcinoma treatment[J]. Liver Cancer, 2012,1(3-4):226-237.
[13]	El-Khoueiry A B, Sangro B, Yau T , et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. The Lancet, 2017,389(10088):2492-2502.
[14]	Yau T, Hsu C, Kim T Y , et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019,71(3):543-552.
[15]	Zhu A X, Finn R S, Edeline J , et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial[J]. LANCET ONCOLOGY, 2018,19(7):940-952.
[16]	Finn Rs R B M P. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).[J] J Clin Oncol. 2019; 37(15_suppl): 4004., 2019.
[17]	Yau T P J F R. CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma. [Z]. 2019.
[18]	Qin S-K R Z M Z. LBA27 arandomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment.[J]. Ann Oncol. 2018;29(suppl_8):mdy424.029., 2018.
[19]	Fang W, Yang Y, Ma Y , et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018,19(10):1338-1350.
[20]	Xu J, Zhang Y, Jia R , et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study[J]. Clin Cancer Res, 2019,25(2):515-523.
[21]	Yau T K Y K T. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate040.[J]. J Clin Oncol. 2019; 37(15_suppl):4012.
[22]	Sangro B, Gomez-Martin C, de la Mata M , et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol, 2013,59(1):81-88.
[23]	Llovet J M, Montal R, Sia D , et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018,15(10):599-616.
[24]	Kudo M, Finn R S, Qin S , et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126):1163-1173.
[25]	Llovet J M, Kudo M, Cheng A L , et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first⌐\line treatment of patients (pts)with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP⌐\002 study.[J]. J. Clin. Oncol., 2019, ( 2019, 37,doi: 10.1200/JCO.2019.37.15_suppl.TPS4152.).
[26]	Sharma P, Allison J P . Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential[J]. Cell, 2015,161(2):205-214.
[27]	Kudo M . Combination Cancer Immunotherapy in Hepatocellular Carcinoma[J]. LIVER CANCER, 2018,7(1):20-27.
[28]	Stein S, Pishvaian M J, Lee M S , et al. Safety and clinical activity of 1L atezolizumab plus bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018,36S(15).
[29]	Cheng A-L Q S I M. IMbrave150: Efficacy and Safety Results From a Ph 3 Study Evaluating Atezolizumab (atezo) + Bevacizumab (bev) vs Sorafenib (Sor) as First Treatment (tx) for Patients (pts) With Unresectable Hepatocellular Carcinoma (HCC). [Z]. 2019.
[30]	Kelley R K, Abou-Alfa G K, Bendel J C, et al. Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I[52]
[31]	Bulliard Y, Jolicoeur R, Zhang J, et al. OX40 engagement depletes intratumoral Tregs via activating Fc gamma Rs, leading to antitumor efficacy[J]. IMMUNOLOGY AND CELL BIOLOGY, 2014,92(6):475-480.
[32]	Guo Z, Wang X, Cheng D , et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer[J]. PLoS One, 2014,9(2):e89350.
[33]	Rech A J, Dada H, Kotzin J J , et al. Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer[J]. Cancer Res, 2018,78(15):4282-4291.
[34]	Duffy A G, Ulahannan S V, Makorova-Rusher O , et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017,66(3):545-551.
[35]	Greten T F, Mauda-Havakuk M, Heinrich B , et al. Combined locoregional-immunotherapy for liver cancer[J]. Journal of Hepatology, 2019,70(5):999-1007.
[36]	Qin S, Cheng Y, Liang J , et al. Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study[J]. Oncologist, 2014,19(11):1169-1178.
[37]	Kyi C, Postow M A . Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges[J]. Immunotherapy, 2016,8(7):821-837.
[38]	Wang W, Wu L, Zhang J , et al. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model[J]. Biochem Biophys Res Commun, 2017,487(1):1-7.
[39]	Qin S E A . Poster 179. [Z]. 2019.
[40]	Juneja V R, Mcguire K A, Manguso R T , et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity[J]. J Exp Med, 2017,214(4):895-904.
[41]	Kleinovink J W, van Hall T, Ossendorp F , et al. PD-L1 immune suppression in cancer: Tumor cells or host cells?[J]. Oncoimmunology, 2017,6(7):e1325982.
[42]	Macek J Z, Aspord C, Kurma K , et al. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment[J]. Clin Transl Gastroenterol, 2019,10(7):e58.
[43]	Goodman A M, Kato S, Bazhenova L , et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers[J]. Molecular Cancer Therapeutics, 2017,16(11):2598-2608.
[44]	Ang C, Klempner S J, Ali S M , et al. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma[J]. Oncotarget, 2019,10(40):4018-4025.
[45]	Boyiadzis M M, Kirkwood J M, Marshall J L , et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease[J]. J Immunother Cancer, 2018,6(1):35.
[46]	Goumard C, Desbois-Mouthon C, Wendum D , et al. Low Levels of Microsatellite Instability at Simple Repeated Sequences Commonly Occur in Human Hepatocellular Carcinoma[J]. Cancer Genomics Proteomics, 2017,14(5):329-339.
[47]	Zhou G, Sprengers D, Boor P , et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas[J]. Gastroenterology, 2017,153(4):1107-1119.
[48]	Kim H D, Song G W, Park S , et al. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8(+) T Cells and Features of Hepatocellular Carcinoma[J]. Gastroenterology, 2018,155(6):1936-1950.
[49]	Feun L G, Li Y Y, Wu C , et al. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma[J]. Cancer, 2019,125(20):3603-3614.
[50]	Zhou J, Mahoney K M, Giobbie-Hurder A , et al. Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade[J]. Cancer Immunol Res, 2017,5(6):480-492.
[51]	Conforti F, Pala L, Bagnardi V , et al. Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis[J]. Lancet Oncol, 2018,19(6):737-746.
[52]	Nosrati A, Tsai K K, Goldinger S M , et al. Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy[J]. Br J Cancer, 2017,116(9):1141-1147.
[53]	Sanmamed M F, Chen L . A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization[J]. Cell, 2019,176(3):677.
[54]	Kugel C R, Douglass S M, Webster M R , et al. Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations[J]. Clin Cancer Res, 2018,24(21):5347-5356.
[55]	Tripathi A, Debelius J, Brenner D A , et al. The gut-liver axis and the intersection with the microbiome[J]. Nat Rev Gastroenterol Hepatol, 2018,15(7):397-411.
[56]	Ponziani F R, Bhoori S, Castelli C , et al. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease[J]. Hepatology, 2019,69(1):107-120.
[57]	Zheng Y, Wang T, Tu X , et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma[J]. J Immunother Cancer, 2019,7(1):193.
[58]	Munker S, De Toni E N . Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018,6(7):970-973.
[59]	Harding J J, Nandakumar S, Armenia J , et al. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies[J]. Clin Cancer Res, 2019,25(7):2116-2126.
[60]	Kambhampati S, Bauer K E, Bracci P M , et al. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series[J]. CANCER, 2019,125(18):3234-3241.